RHJA
UTMD icon

Rice Hall James & Associates’s Utah Medical Products UTMD Stock Holding History

Rice Hall James & Associates’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.21M Buy
67,882
+3,484
+5% +$219K 0.23% 94
2025
Q4 		$3.6M Buy
64,398
+2,967
+5% +$172K 0.2% 112
2025
Q3 		$3.87M Sell
61,431
-6,792
-10% -$402K 0.21% 106
2025
Q2 		$3.88M Sell
68,223
-5,572
-8% -$303K 0.21% 103
2025
Q1 		$4.14M Sell
73,795
-5,013
-6% -$300K 0.24% 89
2024
Q4 		$4.84M Sell
78,808
-4,530
-5% -$293K 0.27% 82
2024
Q3 		$5.58M Buy
83,338
+16,297
+24% +$1.11M 0.3% 77
2024
Q2 		$4.48M Buy
67,041
+2,427
+4% +$165K 0.27% 82
2024
Q1 		$4.59M Sell
64,614
-40,397
-38% -$3.03M 0.26% 85
2023
Q4 		$8.84M Sell
105,011
-6,623
-6% -$549K 0.51% 52
2023
Q3 		$9.6M Sell
111,634
-1,365
-1% -$126K 0.61% 46
2023
Q2 		$10.5M Sell
112,999
-1,124
-1% -$106K 0.6% 49
2023
Q1 		$10.8M Sell
114,123
-243
-0.2% -$22.3K 0.61% 45
2022
Q4 		$11.5M Sell
114,366
-3,172
-3% -$290K 0.66% 43
2022
Q3 		$10M Sell
117,538
-1,352
-1% -$119K 0.58% 46
2022
Q2 		$10.2M Buy
118,890
+2,277
+2% +$194K 0.49% 56
2022
Q1 		$10.5M Buy
116,613
+2,780
+2% +$256K 0.42% 64
2021
Q4 		$11.4M Sell
113,833
-952
-0.8% -$97.1K 0.4% 59
2021
Q3 		$10.7M Buy
114,785
+1,896
+2% +$167K 0.39% 65
2021
Q2 		$9.6M Sell
112,889
-4,107
-4% -$355K 0.34% 67
2021
Q1 		$10.1M Buy
116,996
+12,921
+12% +$1.14M 0.33% 72
2020
Q4 		$8.77M Buy
104,075
+4,628
+5% +$395K 0.31% 70
2020
Q3 		$7.94M Buy
99,447
+27,163
+38% +$2.25M 0.32% 68
2020
Q2 		$6.41M Buy
72,284
+670
+0.9% +$60.1K 0.28% 101
2020
Q1 		$6.74M Sell
71,614
-9,252
-11% -$860K 0.38% 79
2019
Q4 		$8.72M Buy
80,866
+2,247
+3% +$228K 0.3% 110
2019
Q3 		$7.54M Buy
78,619
+566
+0.7% +$52.6K 0.27% 111
2019
Q2 		$7.47M Buy
78,053
+33,064
+73% +$2.78M 0.25% 115
2019
Q1 		$3.97M Buy
44,989
+21,407
+91% +$1.88M 0.13% 135
2018
Q4 		$1.96M Buy
23,582
+20,173
+592% +$1.78M 0.07% 169
2018
Q3 		$321K Sell
3,409
-12
-0.4% -$1.15K 0.01% 285
2018
Q2 		$377K Buy
3,421
+58
+2% +$6.06K 0.01% 276
2018
Q1 		$332K Sell
3,363
-509
-13% -$45.4K 0.01% 274
2017
Q4 		$315K Buy
3,872
+41
+1% +$3.2K 0.01% 284
2017
Q3 		$282K Buy
3,831
+2
+0.1% +$144 0.01% 279
2017
Q2 		$277K Buy
3,829
+40
+1% +$2.63K 0.01% 276
2017
Q1 		$236K Buy
3,789
+114
+3% +$7.18K 0.01% 288
2016
Q4 		$267K Buy
+3,675
New +$239K 0.01% 282

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rice Hall James & Associates's UTMD Position: Q1 2026 in Review

Rice Hall James & Associates increased its Utah Medical Products (UTMD) stake by 5.4% in Q1 2026, buying an estimated $219K and bringing the position to 67,882 shares worth $4.21M. The position accounts for 0.23% of the portfolio, ranked #94.

Rice Hall James & Associates first reported a position in UTMD in Q4 2016 and has held it in 38 quarters since. The position peaked at $11.5M in Q4 2022. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Rice Hall James & Associates held 67,882 shares of Utah Medical Products worth $4.21M as of Q1 2026.
  • Rice Hall James & Associates bought 3,484 Utah Medical Products shares in Q1 2026, an estimated $219K.
  • Utah Medical Products made up 0.23% of Rice Hall James & Associates's portfolio in Q1 2026, its #94 holding.
  • Rice Hall James & Associates first reported a position in Utah Medical Products in Q4 2016 and has held it in 38 quarters since.
  • Rice Hall James & Associates's Utah Medical Products position peaked at $11.5M in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.